BC Week In Review | Oct 13, 2014
Company News

Genetic Technologies sales and marketing update

Genetic Technologies' Phenogen Sciences Inc. subsidiary launched BREVAGenplus in the U.S. to assess a women's risk of developing sporadic or non-hereditary breast cancer. According to Genetic Technologies, the test is designed for Caucasian, Hispanic and...
BC Week In Review | Sep 29, 2014
Company News

Genetic Technologies diagnostic news

Genetic Technologies announced plans to restructure and realign activities to focus on the U.S. molecular diagnostics market and commercialization of its BREVAGen test. Genetic Technologies markets BREVAGen to determine an individual's risk of developing non-familial...
BC Week In Review | Mar 17, 2014
Clinical News

BREVAGen diagnostic data

Data from Caucasian women with an intermediate 5-year risk of developing breast cancer in a U.S. cost-effectiveness study showed that the incremental cost-effectiveness ratio (ICER) for using the BREVAGen test plus a clinical risk assessment...
BioCentury | Feb 17, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/14 cls Depomed Inc. (NASDAQ:DEPO) Roth Capital Partners Scott Henry Downgrade Neutral (from buy) 1% $12.30 Henry downgraded on the belief that the share...
BC Week In Review | Sep 9, 2013
Clinical News

BREVAGen regulatory update

Genetic Technologies said the New York State Department of Health issued a clinical laboratory permit to allow the company to perform its BREVAGen genetic test to determine an individual's risk of developing non-familial breast cancer....
BC Week In Review | Aug 13, 2012
Clinical News

BREVAGen regulatory update

Genetic Technologies received CE Mark approval for its BREVAGen genetic test to determine an individual's risk of developing non-familial breast cancer. The breast cancer stratification test combines a DNA-based profile of breast cancer-associated SNPs with...
BC Week In Review | Jun 27, 2011
Company News

Genetic Technologies sales and marketing update

Genetic Technologies' Phenogen Sciences Inc. subsidiary launched the BREVAGen genetic test in the U.S. to determine a patient's lifetime and five-year risk for developing non-familial breast cancer. The breast cancer stratification test combines a DNA-based...
BC Week In Review | Apr 26, 2010
Company News

Genetic Technologies, Perlegen deal

Genetic Technologies said it acquired essentially all of Perlegen's assets, including all rights related to Perlegen's BREVAGen breast cancer stratification test and a suite of international patents valid until 2022 related to genomic mapping and...
BC Week In Review | Sep 28, 2009
Company News

Perlegen sales and marketing update

Perlegen launched its BREVAGen breast cancer stratification test in selected U.S. markets. The test combines a DNA-based profile of breast cancer-associated SNPs with the patient's clinical history to determine the patient's lifetime and five-year risk...
Items per page:
1 - 9 of 9